<DOC>
	<DOC>NCT00761319</DOC>
	<brief_summary>The purpose of the study is to compare two ophthalmic solutions in patients with open-angle glaucoma or ocular hypertension.</brief_summary>
	<brief_title>Phase III Clinical Trial of TRAVATAN Z in Ocular Surface Health</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>18 years or older. Ocular Surface Disease Index (OSDI) score and corneal fluorescein staining score as specified in protocol. Diagnosis of openangle glaucoma or ocular hypertension in at least one eye. Intraocular pressure (IOP) controlled with latanoprost 0.005% (XALATANÂ®) for at least one continuous month prior to Visit 1. Willing and able to discontinue use of any topical ocular medicine other than the study medication for the duration of the study, including artificial tears. Best corrected visual acuity of 0.6 logMAR or better in each eye. Other protocoldefined inclusion criteria may apply. Any medical condition (systemic or ophthalmic) that may preclude safe administration of the test article. Use of contact lenses within 30 days of Visit 1. Use of contact lenses during the study. Participation in an investigational drug or device study within 30 days of entering this study. Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Open-angle glaucoma</keyword>
	<keyword>ocular hypertension</keyword>
</DOC>